Vor Biopharma (NASDAQ:VOR) Cut to Sell at Wall Street Zen

Vor Biopharma (NASDAQ:VOR) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

VOR has been the topic of several other reports. William Blair assumed coverage on Vor Biopharma in a research report on Wednesday, October 21st. They set an “outperform” rating on the stock. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Finally, Wedbush increased their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Vor Biopharma Stock Performance

Shares of VOR opened at $19.68 on Friday. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $26.76. The company has a 50-day moving average of $20.75 and a two-hundred day moving average of $17.33.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Friday, October 30th. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64). On average, equities research analysts expect that Vor Biopharma will post -2.56 earnings per share for the current year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Vor Biopharma in the 3rd quarter valued at $58,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vor Biopharma by 25.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock valued at $198,000 after acquiring an additional 2,171 shares in the last quarter. Engineers Gate Manager LP raised its position in Vor Biopharma by 37.5% during the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after acquiring an additional 10,071 shares in the last quarter. Braidwell LP lifted its position in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after buying an additional 106,330 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in shares of Vor Biopharma during the 2nd quarter worth $499,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.